Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Editas Medicine, Inc.EDIT · Entity 5502 | Director | June 15, 2017 | June 19, 2017 |
| FATE THERAPEUTICS INCFATE · Entity 5968 | Director | May 29, 2025 | May 30, 2025 |
| Moderna, Inc.MRNA · Entity 2025 | See Remarks | December 07, 2018 | December 07, 2018 |
| Omega Therapeutics, Inc.OMGA · Entity 83618 | Director | June 20, 2024 | June 21, 2024 |
| aTYR PHARMA INCLIFE · Entity 7233 | Director | May 08, 2019 | May 10, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Editas Medicine, Inc.
Report date June 15, 2017 · Filed June 19, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.63 · Expires 2027-06-14 | Direct | 11,538 |
Reported balance
After 2017-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-15 · Grant · Acquired 11,538 · Balance 11,538 F1: This option was granted on June 15, 2017 and is scheduled to vest in full on June 15, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 15, 2017 and is scheduled to vest in full on June 15, 2018.
FATE THERAPEUTICS INC
Report date May 29, 2025 · Filed May 30, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.32 · Expires 2035-05-29 | Direct | 55,000 |
Reported balance
After 2025-05-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-29 · Grant · Acquired 55,000 · Balance 55,000 F1: This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders. F2: The shares subject to this option shall vest and become exercisable on the earlier of (i) May 29, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders.
F2: The shares subject to this option shall vest and become exercisable on the earlier of (i) May 29, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.
Moderna, Inc.
Report date December 07, 2018 · Filed December 07, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 806,154 |
Reported balance
Holding disclosure · report date 2018-12-07 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 806,154 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.90 · Expires 2026-02-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2018-12-07 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: This option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.15 · Expires 2026-08-10 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2018-12-07 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F2: This option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.21 · Expires 2027-02-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2018-12-07 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F3: This option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.22 · Expires 2028-02-28 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2018-12-07 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F4: 1,834,863 options will vest over 4 years, with 25% vesting on January 2, 2019, and the remaining 75% vesting in equal calendar quarterly installments over the next three years; 688,073 options will vest over 5 years, with 25% vesting on January 2, 2020, and the remaining 75% vesting in equal calendar quarterly installments over the following three years; and 458,715 options will vest over 6 years, with 25% vesting on January 2, 2021, and the remaining 75% vesting in equal calendar quarterly installments over the following three years. |
Filing footnotes · ownership attribution and instrument terms
F1: This option is fully vested and exercisable.
F2: This option is fully vested and exercisable.
F3: This option is fully vested and exercisable.
F4: 1,834,863 options will vest over 4 years, with 25% vesting on January 2, 2019, and the remaining 75% vesting in equal calendar quarterly installments over the next three years; 688,073 options will vest over 5 years, with 25% vesting on January 2, 2020, and the remaining 75% vesting in equal calendar quarterly installments over the following three years; and 458,715 options will vest over 6 years, with 25% vesting on January 2, 2021, and the remaining 75% vesting in equal calendar quarterly installments over the following three years.
Omega Therapeutics, Inc.
Report date June 20, 2024 · Filed June 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.20 · Expires 2034-06-19 | Direct | 25,000 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 25,000 · Balance 25,000 F1: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.
aTYR PHARMA INC
Report date May 08, 2019 · Filed May 10, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.58 · Expires 2029-05-08 | Direct | 20,000 |
Reported balance
After 2019-05-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-05-08 · Grant · Acquired 20,000 · Balance 20,000 F1: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 8, 2020 or (ii) the Issuer's 2020 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 8, 2020 or (ii) the Issuer's 2020 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 29, 2025 Filed May 30, 2025 20:08 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0000950170-25-079716 · ownership.xml · derivative · entry 1 MENDLEIN JOHN · CIK 0001238362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2035-05-29 F1 · kind: This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders. F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) May 29, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 16:20 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0000950170-24-076264 · ownership.xml · derivative · entry 1 MENDLEIN JOHN · CIK 0001238362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:27 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $3.68 | $0.00 |
DisclosureSEC source: 0000950170-24-071941 · ownership.xml · derivative · entry 1 MENDLEIN JOHN · CIK 0001238362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-06-07 F1 · kind: This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders. F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) June 7, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 16:05 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | GrantStock Option (Right to Buy) · Derivative | 18,118 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0000899243-23-015149 · doc4.xml · derivative · entry 1 MENDLEIN JOHN · CIK 0001238362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,118 Underlying: Common Stock · 18,118 shares Expires 2033-06-06 F1 · derivative.exercise_date: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. Read SEC document |
| June 06, 2023 Filed Jun 7, 2023 20:11 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $5.52 | $0.00 |
DisclosureSEC source: 0001209191-23-035059 · doc4.xml · derivative · entry 1 MENDLEIN JOHN · CIK 0001238362 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-06-06 F1 · kind: This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders. F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) June 6, 2024 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document |
| January 19, 2023 Filed Jan 20, 2023 21:14 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 28,461 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0001209191-23-004237 · doc4.xml · derivative · entry 2 MENDLEIN JOHN · CIK 0001238362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,461 shares Expires 2023-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This stock option is fully vested and exercisable. Read SEC document |
| January 19, 2023 Filed Jan 20, 2023 21:14 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 28,461 | $1.37 | $38,991.57 |
DisclosureSEC source: 0001209191-23-004237 · doc4.xml · nonDerivative · entry 1 MENDLEIN JOHN · CIK 0001238362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 13, 2023 Filed Jan 13, 2023 23:20 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | PurchaseCommon Stock | 36,631 | $5.43 | $198,906.33 |
DisclosureSEC source: 0001209191-23-003338 · doc4.xml · nonDerivative · entry 2 MENDLEIN JOHN · CIK 0001238362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,770 Read SEC document |
| January 11, 2023 Filed Jan 13, 2023 23:20 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | PurchaseCommon Stock | 88,048 | $5.67 | $499,232.16 |
DisclosureSEC source: 0001209191-23-003338 · doc4.xml · nonDerivative · entry 1 MENDLEIN JOHN · CIK 0001238362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,139 Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:42 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 11,893 | $0.00 Strike: $23.48 | $0.00 |
DisclosureSEC source: 0001209191-22-036350 · doc4.xml · derivative · entry 2 MENDLEIN JOHN · CIK 0001238362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,893 Underlying: Common Stock · 11,893 shares Expires 2032-06-09 F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) June 9, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:42 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon Stock | 8,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-036350 · doc4.xml · nonDerivative · entry 1 MENDLEIN JOHN · CIK 0001238362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,741 F1 · security: Award of restricted stock units that vest in full on the earlier of (i) June 9, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 16:10 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | GrantOption (Right to Buy) · Derivative | 18,118 | $0.00 Strike: $3.31 | $0.00 |
DisclosureSEC source: 0000899243-22-021897 · doc4.xml · derivative · entry 1 MENDLEIN JOHN · CIK 0001238362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,118 Underlying: Common Stock · 18,118 shares Expires 2032-06-07 F1 · derivative.exercise_date: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. Read SEC document |
| June 03, 2022 Filed Jun 6, 2022 20:49 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 1,364 | $22.79 | $31,085.56 |
DisclosureSEC source: 0001209191-22-034554 · doc4.xml · nonDerivative · entry 1 MENDLEIN JOHN · CIK 0001238362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,091 F1 · kind: Required number of shares sold by the reporting person to cover tax obligations in connection with the vesting of 2,681 shares of Common Stock underlying RSUs granted to the reporting person on June 2, 2021. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: Represents the weighted average sale price of the shares sold from $22.53 to $22.92 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 21:58 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionStock Option (Right to Buy) · Derivative | 31,562 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001209191-22-018188 · doc4.xml · derivative · entry 4 MENDLEIN JOHN · CIK 0001238362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,562 shares Expires 2022-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 21:58 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 12,069 | $35.48 | $428,208.12 |
DisclosureSEC source: 0001209191-22-018188 · doc4.xml · nonDerivative · entry 3 MENDLEIN JOHN · CIK 0001238362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,455 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. F3 · price: Represents the weighted average sale price of the shares sold from $35.13 to $35.75 per share. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 21:58 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 19,493 | $34.73 | $676,991.89 |
DisclosureSEC source: 0001209191-22-018188 · doc4.xml · nonDerivative · entry 2 MENDLEIN JOHN · CIK 0001238362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,524 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. F2 · price: Represents the weighted average sale price of the shares sold from $34.12 to $35.11 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of he Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 3. Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 21:58 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | Exercise / conversionCommon Stock | 31,562 | $1.63 | $51,446.06 |
DisclosureSEC source: 0001209191-22-018188 · doc4.xml · nonDerivative · entry 1 MENDLEIN JOHN · CIK 0001238362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,017 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:24 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 4,334 | $0.00 Strike: $68.94 | $0.00 |
DisclosureSEC source: 0000899243-21-022076 · doc4.xml · derivative · entry 2 MENDLEIN JOHN · CIK 0001238362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,334 Underlying: Common Stock · 4,334 shares Expires 2031-06-01 F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) June 2, 2022 or (ii) the date of the Issuer's 2022 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:24 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon Stock | 2,681 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022076 · doc4.xml · nonDerivative · entry 1 MENDLEIN JOHN · CIK 0001238362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,455 F1 · security: Award of restricted stock units that vest in full on the earlier of (i) June 2, 2022 or (ii) the date of the Issuer's 2022 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:17 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 16,000 | Not disclosed Strike: $26.59 | Not disclosed |
DisclosureSEC source: 0001209191-20-027100 · doc4.xml · derivative · entry 1 MENDLEIN JOHN · CIK 0001238362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2030-05-01 F2 · price: Not applicable. F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) May 1, 2021 or (ii) the date of the Issuer's 2021 Annual Meeting of Stockholders, subject to the recipient's continued service on the Issuer's Board of Directors. Read SEC document |
| May 08, 2019 Filed May 10, 2019 17:29 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001209191-19-029044 · doc4.xml · derivative · entry 1 MENDLEIN JOHN · CIK 0001238362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-05-08 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 8, 2020 or (ii) the Issuer's 2020 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| May 03, 2019 Filed May 7, 2019 20:05 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 16,000 | Not disclosed Strike: $17.15 | Not disclosed |
DisclosureSEC source: 0001209191-19-027950 · doc4.xml · derivative · entry 1 MENDLEIN JOHN · CIK 0001238362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2029-05-03 F2 · price: Not applicable. F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) May 3, 2020 or (ii) the date of the Issuer's 2020 Annual Meeting of Stockholders, subject to the recipient's continued service on the Issuer's Board of Directors. Read SEC document |
| December 21, 2018 Filed Dec 26, 2018 16:15 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 195,000 | $0.42 | $82,602.00 |
DisclosureSEC source: 0001209191-18-064090 · doc4.xml · nonDerivative · entry 2 MENDLEIN JOHN · CIK 0001238362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 615,382 F2 · price: Represents weighted average price for the shares. The shares were purchased at price ranging from $0.4048 to $0.4300 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 20, 2018 Filed Dec 26, 2018 16:15 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 50,000 | $0.41 | $20,645.00 |
DisclosureSEC source: 0001209191-18-064090 · doc4.xml · nonDerivative · entry 1 MENDLEIN JOHN · CIK 0001238362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,382 F1 · price: Represents weighted average price for the shares. The shares were purchased at price ranging from $0.4013 to $0.4100 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| May 15, 2018 Filed May 17, 2018 16:32 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001209191-18-030926 · doc4.xml · derivative · entry 1 MENDLEIN JOHN · CIK 0001238362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-05-15 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 15, 2019 or (ii) the Issuer's 2019 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| May 02, 2018 Filed May 4, 2018 20:19 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 16,000 | Not disclosed Strike: $9.78 | Not disclosed |
DisclosureSEC source: 0001209191-18-028103 · doc4.xml · derivative · entry 1 MENDLEIN JOHN · CIK 0001238362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2028-05-02 F2 · price: Not applicable. F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) May 2, 2019 or (ii) the date of the 2019 Annual Meeting of Stockholders, subject to the recipient's continued service on the Issuer's Board of Directors. Read SEC document |
| January 02, 2018 Filed Jan 2, 2018 19:49 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantStock Option (right to buy) · Derivative | 32,000 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001209191-18-000388 · doc4.xml · derivative · entry 2 MENDLEIN JOHN · CIK 0001238362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2028-01-02 F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 36 equal monthly installments beginning February 2, 2018, such that this option will be fully exercisable on January 2, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 19:41 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseWarrant to Purchase Common Stock · Derivative | 14,151 | Not disclosed Strike: $4.64 | Not disclosed |
DisclosureSEC source: 0001209191-17-051470 · doc4.xml · derivative · entry 2 MENDLEIN JOHN · CIK 0001238362 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,151 Underlying: Common Stock · 14,151 shares Expires 2019-12-31 F1 · shares: Represents shares acquired in a private placement pursuant to a Securities Purchase Agreement dated August 27, 2017 by and among the Company and a select group of institutional and accredited investors named therein (the "Securities Purchase Agreement"). Pursuant to the terms of the Securities Purchase Agreement, investors purchased common stock units for $2.65 per common stock unit. Each common stock unit consisted of one share of the Company's Common Stock and a warrant to purchase 0.375 shares of the Company's Common Stock. F1 · price: Represents shares acquired in a private placement pursuant to a Securities Purchase Agreement dated August 27, 2017 by and among the Company and a select group of institutional and accredited investors named therein (the "Securities Purchase Agreement"). Pursuant to the terms of the Securities Purchase Agreement, investors purchased common stock units for $2.65 per common stock unit. Each common stock unit consisted of one share of the Company's Common Stock and a warrant to purchase 0.375 shares of the Company's Common Stock. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 19:41 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 37,736 | $2.65 | $100,000.40 |
DisclosureSEC source: 0001209191-17-051470 · doc4.xml · nonDerivative · entry 1 MENDLEIN JOHN · CIK 0001238362 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,883 F1 · shares: Represents shares acquired in a private placement pursuant to a Securities Purchase Agreement dated August 27, 2017 by and among the Company and a select group of institutional and accredited investors named therein (the "Securities Purchase Agreement"). Pursuant to the terms of the Securities Purchase Agreement, investors purchased common stock units for $2.65 per common stock unit. Each common stock unit consisted of one share of the Company's Common Stock and a warrant to purchase 0.375 shares of the Company's Common Stock. F1 · price: Represents shares acquired in a private placement pursuant to a Securities Purchase Agreement dated August 27, 2017 by and among the Company and a select group of institutional and accredited investors named therein (the "Securities Purchase Agreement"). Pursuant to the terms of the Securities Purchase Agreement, investors purchased common stock units for $2.65 per common stock unit. Each common stock unit consisted of one share of the Company's Common Stock and a warrant to purchase 0.375 shares of the Company's Common Stock. F2 · balance_after: Includes 2,500 shares acquired under the Company's 2015 Employee Stock Purchase Plan (ESPP) on May 15, 2017. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 16:09 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 11,538 | $0.00 Strike: $15.63 | $0.00 |
DisclosureSEC source: 0001179110-17-009260 · edgar.xml · derivative · entry 1 MENDLEIN JOHN · CIK 0001238362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,538 Underlying: Common Stock · 11,538 shares Expires 2027-06-14 F1 · derivative.exercise_date: This option was granted on June 15, 2017 and is scheduled to vest in full on June 15, 2018. Read SEC document |
| May 02, 2017 Filed May 4, 2017 16:02 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $4.73 | Not disclosed |
DisclosureSEC source: 0001209191-17-029932 · doc4.xml · derivative · entry 1 MENDLEIN JOHN · CIK 0001238362 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-05-01 F2 · price: Not applicable. F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) May 2, 2018 or (ii) the date of the 2018 Annual Meeting of Stockholders, subject to the recipient's continued service on the Issuer's Board of Directors. Read SEC document |
| April 24, 2017 Filed Apr 26, 2017 17:02 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 124 | $3.00 | $372.00 |
DisclosureSEC source: 0001209191-17-028224 · doc4.xml · nonDerivative · entry 1 MENDLEIN JOHN · CIK 0001238362 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,647 F1 · kind: The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 21, 2016. Read SEC document |
| April 20, 2017 Filed Apr 20, 2017 19:04 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 1,552 | $3.00 | $4,656.00 |
DisclosureSEC source: 0001209191-17-027776 · doc4.xml · nonDerivative · entry 2 MENDLEIN JOHN · CIK 0001238362 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,523 F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 21, 2016. Read SEC document |
| April 18, 2017 Filed Apr 20, 2017 19:04 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 1,000 | $3.00 | $3,000.00 |
DisclosureSEC source: 0001209191-17-027776 · doc4.xml · nonDerivative · entry 1 MENDLEIN JOHN · CIK 0001238362 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,971 F1 · kind: The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 21, 2016. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 16:27 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantEmployee Stock Option (right to buy) · Derivative | 185,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001209191-17-009086 · doc4.xml · derivative · entry 1 MENDLEIN JOHN · CIK 0001238362 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2027-03-07 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 7, 2017, such that this option will be fully exercisable on February 7, 2021. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Read SEC document |
| December 19, 2016 Filed Dec 21, 2016 11:54 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 69,000 | $2.20 | $151,662.00 |
DisclosureSEC source: 0001209191-16-156269 · doc4.xml · nonDerivative · entry 1 MENDLEIN JOHN · CIK 0001238362 · Director · CEO and Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,971 F1 · price: Represents the weighted average price for the shares. The shares were purchased at prices ranging from $2.125 to $2.25 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 2,500 shares acquired under the Company's 2015 Employee Stock Purchase Plan ("ESPP") on May 15, 2016 and 2,500 shares acquired under the ESPP on November 15, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.